Fertility Preservation Iatrogenic denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for FERTILITY PRESERVATION IATROGENIC are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Fertility Preservation (Iatrogenic) Under "Step Therapy"

Step therapy — the requirement to try a less expensive or more conservative option before a preferred treatment is covered — is a common insurer tool for medication management. When applied to iatrogenic fertility preservation, however, it is often clinically inapplicable: there is no meaningful "step" that can precede oocyte cryopreservation or embryo banking before a patient begins chemotherapy. A step-therapy denial in this context frequently reflects a policy template being applied to the wrong clinical scenario, and it is almost always worth challenging directly.

## Why This Denial Is Appealable

Step-therapy requirements, when applied to time-sensitive interventions where prior steps are medically impossible or clinically inappropriate, are routinely overturned on appeal. Federal and many state laws require insurers to grant step-therapy exceptions when the required prior therapy is contraindicated, has already been tried, or would cause irreversible harm if pursued first. For iatrogenic fertility preservation, the "harm of delay" argument is concrete: once gonadotoxic treatment begins, the window for preservation closes permanently.

## Federal Appeal Framework

• Internal appeal: Under ERISA §503 or ACA §2719, you have a right to a full and fair review of any adverse benefit determination. In your appeal, cite the specific step-therapy exception criteria in Aetna's own policy or in the applicable state step-therapy law.
• State step-therapy protections: Many states have enacted step-therapy exception laws that set mandatory timelines (often 72 hours for urgent requests). Check whether your plan is state-regulated (fully-insured) or ERISA-governed (self-funded employer plan), as state laws apply only to the former.
• External review: After an adverse internal decision, request IRO review within approximately four months. The IRO will assess whether the step-therapy override criteria are met.
• Expedited review: Given the time constraint imposed by the oncology treatment schedule, request expedited processing with physician attestation of urgency.

## Documentation to Gather

• Clinical urgency letter: A letter from your oncologist stating the treatment start date, the gonadotoxic agents involved, and why fertility preservation cannot be deferred.
• Step-therapy exception basis: Identify which exception category applies — most commonly "the required prior therapy is not clinically appropriate for this patient" or "delay would result in irreversible harm." Have your reproductive endocrinologist state this explicitly.
• Prescriber medical-necessity letter: From both the oncologist and the reproductive endocrinologist, jointly documenting why the requested preservation approach is the appropriate first-line intervention for this patient's circumstances.
• Guideline organization references: Reference ASCO oncofertility guidance and ASRM practice committee opinions generically, without quoting specific numbers.
• Aetna's step-therapy policy: Obtain the exact step-therapy requirements and the listed exception criteria from Aetna's published policy.

## Criteria-Mapping Structure

| Step-Therapy Requirement / Exception Criterion | Source | How Your Case Qualifies | |---|---|---| | [Verbatim step or exception language from Aetna policy] | [Policy name/section] | [Chart fact, physician statement, date] |

In the narrative, be explicit: state the exception you are invoking, cite the policy language that establishes it, and map each required element to your specific clinical facts. Request a response within the expedited timeframe given the oncology treatment schedule.